Navigation Links
VaxInnate to discuss seasonal and pandemic flu vaccines during BIO 2008 this week
Date:6/15/2008

SAN DIEGO, CA, June 16, 2008 -- VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week.

VaxInnate will participate in the following three BIO 2008 panel discussions:

On Tuesday, June 17th

  • "Influenza Research and Surveillance: Preparing for the Next Pandemic,"
    8:15-9:45 am in Room 29A including Robert Becker, PhD, MBA, VaxInnate's Vice President of Business Development

On Thursday, June 19th

  • "Vaccine Renaissance,"
    8:30-10:00 am, Room 29A including Dr. Robert Becker

  • "Moore's Law for Biomanufacturing: Innovation in a Maturing Biologicals Industry,"
    4:00 - 5:30 pm, Room 29B including Edward Arcuri, PhD, VaxInnate's Chief of Operations (COO)

VaxInnate's Approach

VaxInnate's novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.

VaxInnate's approach to developing and producing influenza vaccines is based upon a proprietary combination of toll-like receptor (TLR) mediated immune enhancement and recombinant bacterial production of vaccine antigen. This proprietary technology could significantly reduce the time required to produce supplies of influenza vaccine sufficient to meet national and even global needs.

VaxInnate's use of bacterial expression for production of influenza vaccines does not require costly expansion of manufacturing capacity, as do other influenza vaccine products. Due to its efficiency and transferability, VaxInnate's flu vaccine could instead be produced in existing biotechnology facilities that have microbial production capacity.

No other vaccine technology in use or in development today has these same potential capabilities.

Results of a Phase I study of VaxInnate's M2e
'/>"/>

Contact: Janet Skidmore
skidmorecomm@earthlink.net
215-658-4915
VaxInnate
Source:Eurekalert

Page: 1 2

Related biology news :

1. Scientists, policymakers and industry leaders gather to discuss ocean iron fertilization
2. Book on weeds and invasive plants discusses how to manage them using ecological approaches
3. Presidents of Iceland, Bangladesh to discuss global climate change in New Orleans
4. Art meets science: Engineer discusses his photographs in free UH lecture
5. Leading researchers and experts gather to discuss latest advancements in drug discovery
6. Japanese and German researchers meet to discuss climate change
7. Biophysical Society to host discussions on the teaching of evolution and on the energy crisis
8. MIT professor to discuss future of biofuels
9. DHS, business leaders discuss technology to protect US at Homeland Security conference
10. Wildlife Conservation Society study finds seasonal seas save corals with tough love
11. NASA technology helps predict and prevent future pandemic outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... UPTON, NY - A study at the U.S. Department of ... "tagged" with a radioactive form of carbon can be used ... estrogen, in the human brain. The research, published in the ... regions of the brain where aromatase is concentrated may be ...
... breakthrough by scientists at the University of Sheffield has shed ... the land over 470 million years ago by forming a ... today (2 November 2010) in Nature Communications , has ... worked together with soil-dwelling fungi to ,green, the Earth in ...
... 2010 CONRAD, leaders in reproductive health and HIV prevention ... Agency for International Development (USAID). The grant will fund ... also prevent HIV and STI infections. USAID ... conducted by the Centre for Programme Research for AIDS in ...
Cached Biology News:PET scans reveal estrogen-producing hotspots in human brain 2Study shows how ancient plants and soil fungi turned the Earth green 2USAID awards $5 million to CONRAD 2
(Date:7/30/2015)... and Dallas, TX, USA (PRWEB) , ... July ... ... innovative nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development ...
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Regional Cancer PatientsNEW ORLEANS, April 28 Ochsner Health ... Health Sciences Center , New Orleans ( www.lsuhsc.edu ... the region,s cancer patients by combining clinical care and ... and provide better access to care. This collaboration will ...
... could prove efficacious for both prophylactic and ... Corporation (NYSE AMEX: CVM ) ... that vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand ... potentially induce protection against illnesses such as ...
... 28 PharmAthene, Inc. (NYSE Amex: PIP ... and chemical threats, announced today that results from a ... at the 12th Annual Conference on Vaccine Research, being ... is sponsored by the National Foundation of Infectious Diseases.David ...
Cached Biology Technology:Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7
... KLH-conjugated, synthetic peptide corresponding to ... mouse p19ARF. The epitope ... 62-75. Clone 5-C3-1. Quality ... immunoblot. Stability ...
EDG-1 Western blot control Source: Cell Lysate Application: Western Blotting Control...
Complete cell culture media with cytokines...
...
Biology Products: